Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...